论文部分内容阅读
目的评价平消胶囊加放射联合治疗Ⅲ期非小细胞肺癌的疗效。方法８０例不能手术的Ⅲ期非小细胞肺癌（ＮＳＣＬＣ）病人被随机分两组：４０例口服平消胶囊，从放疗开始到结束，每次６～８次粒，每日三次（联合组）；４０例单纯放疗（单放组）。两组放疗方法剂量一样，常规分割，每次１．８～２ＧＹ，每周５次，总量６０～７０ＧＹ。结果联合组总有效率９０％，ＣＲ３５％，中位生存期１８个月，单放组分别为６５％、１５％，１０个月。两组总有效率及生存期均有显著差异（Ｐ＜０．０５）。联合组的毒副反应轻，病人免疫力也提高。结论平消胶囊加放射治疗不能手术的Ⅲ期ＮＳＣＬＣ，生存期优于单纯放疗，减轻放疗副作用。
Objective To evaluate the efficacy of Pingxiao capsule plus radiotherapy in the treatment of stage III non-small cell lung cancer. Methods 80 inoperable patients with stage III non-small cell lung cancer (NSCLC) were randomly divided into two groups: 40 cases of Pingxiao capsules, from the beginning to the end of radiotherapy, 6-8 capsules each time, three times daily (combined group) 40 cases of radiotherapy alone (single release group). The doses of the two groups of radiotherapy methods were the same and were routinely divided, each time being 1.8 to 2 GY, 5 times per week, and the total amount was 60 to 70 GY. Results The combined group had a total effective rate of 90%, a CR of 35%, a median survival period of 18 months, and a radiotherapy group of 65%, 15%, and 10 months, respectively. The total effective rate and survival time of the two groups were significantly different (P<0.05). The toxicity of the combination group was lighter, and the patient’s immunity was also increased. Conclusion Pingxiao Capsule plus radiotherapy can not survive stage III NSCLC, and its survival period is better than that of radiotherapy alone, which can reduce the side effects of radiotherapy.